FDA Dietary Supplement Requirements: What “Approval” Actually Means (2026)
By Tam Nguyen | CEO, GOL Solution | 24+ years in international trade & cross-border logistics
Last Updated: August 2026
Dietary supplements do not go through FDA approval before they reach the U.S. market. That single fact surprises most first-time brands, and it cuts both ways: there is no pre-market review to pass, but there is no FDA stamp confirming safety either. The responsibility for compliance sits entirely with the manufacturer and importer, across facility registration, labeling, claims, and ingredient safety.
This guide covers what dietary supplement companies actually need to do to bring a product into the U.S. compliantly, including the requirements most first-time brands miss entirely.
What Are Dietary Supplements?
Dietary supplements are products intended to augment the diet, sold in forms such as tablets, capsules, powders, gummies, and liquids. They differ from conventional food and from drugs: a product intended to diagnose, treat, cure, or prevent a disease is regulated as a drug, regardless of how it’s marketed or labeled.
Typical supplement categories include:
- Vitamins and minerals (multivitamins, vitamin D, calcium, iron)
- Botanicals and herbs (echinacea, ginger, curcumin)
- Amino acids (tryptophan, glutamine)
- Live microbials, commonly marketed as probiotics
The FDA regulates dietary supplements as a category of food, not as drugs. That classification is exactly why there’s no pre-market approval process, and exactly why the compliance burden falls on the company rather than the agency.
Do Dietary Supplements Need FDA Approval?
No. Under the Dietary Supplement Health and Education Act (DSHEA) of 1994, the FDA does not pre-approve dietary supplements for safety, efficacy, or labeling before they reach the market. This is a deliberate structural choice that distinguishes supplements from drugs, and it means the company selling the product, not the FDA, is legally responsible for ensuring it complies with every applicable requirement before the first unit ships.
Not needing approval does not mean not needing compliance. The requirements below apply regardless of the absence of a pre-market review.
FDA Requirements for Bringing a Dietary Supplement to the U.S. Market
Facility Registration
Facilities that manufacture, process, pack, or hold dietary supplements for the U.S. market must register with the FDA, the same requirement that applies to other FDA-regulated food facilities. Registration must be renewed every two years, and foreign facilities need a U.S. agent on file.
FSVP for Supplement Importers
Dietary supplements imported into the U.S. fall under the Foreign Supplier Verification Program (FSVP). The importer of record needs a supplier verification program, evidence of supplier audits, and a Letter of Consent in place before the shipment arrives. FDA product registration and FSVP compliance are separate obligations. Having one does not satisfy the other.
The Supplement Facts Label
Labels must carry a Supplement Facts panel listing serving size, servings per container, and the full list of dietary ingredients with quantity per serving. The product must also be identified on the front label as a “dietary supplement” or an equivalent term.
Structure/Function Claim Notification (the 30-Day Requirement)
If a supplement label makes a structure/function claim, a general well-being claim, or a classical nutrient deficiency claim, the company must notify the FDA in writing within 30 days of first marketing the product with that claim, under 21 CFR 101.93(a). This is one of the most commonly missed requirements we see. Brands assume that because there’s no pre-approval, there’s no filing obligation at all, but the 30-day notification is mandatory and separate from labeling itself.
Any product making this type of claim must also carry the standard disclaimer, in boldface: “This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”
New Dietary Ingredient (NDI) Notification
If a product contains a dietary ingredient that was not marketed in the U.S. before October 15, 1994, the manufacturer or distributor must submit a New Dietary Ingredient notification to the FDA at least 75 days before introducing the product into interstate commerce. Introducing an NDI-containing product without a timely notification makes the product adulterated under the FD&C Act.
Where Claims Cross Into OTC Drug Territory
A supplement’s classification depends heavily on what the label claims, not just what’s in the bottle. Claims that treat, cure, prevent, or alleviate a disease push a product out of the supplement category and into OTC drug or unapproved new drug territory, which carries a far more demanding regulatory path. This is one of the most frequent issues we see during R&D and label review, and it’s avoidable with a claims check before formulation is finalized.
GOL Insight
Most supplement brands that come to us are not aware that the structure/function claim filing is mandatory within 30 days of first distributing a product in the U.S. market. We handle the full registration scope for clients: facility registration, label review, function claim filing, and FSVP compliance, so nothing sits unfiled after launch.
We also support brands earlier, during R&D, by reviewing ingredients and proposed claims against FDA requirements before formulation is locked. A recurring issue we catch is claims language drifting into OTC drug territory. When that happens, we revise the label claims to keep the product classified and compliant as a dietary supplement rather than triggering a drug review pathway.
Should Your Brand Use a Label Review Service?
Label review is not a mandatory FDA filing on its own, so brands can technically skip it. We recommend it strongly for regular clients, and we require it for any client using our FSVP service, because the two are directly connected: an FSVP importer of record carries legal responsibility for the products they bring in, and a label error discovered at the border becomes their problem, not just the brand’s.
Client Experience
We’ve worked with brands that decided to skip label review because they had already reviewed the label internally. In one case, the brand shipped their first Amazon FBA shipment without our review, and FDA rejected it on arrival. The shipment, worth roughly $10,000, was destroyed.
The rejection traced back to two issues: the Supplement Facts panel was in the wrong format, and the declared value on the shipment did not match the value determined during FDA’s review of the product. Either issue alone can be enough to trigger a rejection.
This risk has grown, not shrunk, for online and DTC brands. Effective July 9, 2025, CBP and the FDA removed the Section 321 de minimis exemption for FDA-regulated products, which previously let many low-value e-commerce shipments (informally, under $800) move with minimal FDA review. That workaround is gone. Every FDA-regulated shipment, regardless of value, is now subject to full review, which makes label accuracy non-negotiable for brands planning to sell on Amazon or direct-to-consumer in the U.S. long term.
FDA’s Ongoing Role After Market Entry
Because supplements enter the market without FDA notification, the agency’s regulatory role is almost entirely post-market. The FDA inspects manufacturing facilities for compliance with labeling and manufacturing standards, reviews product labels and marketing claims (including online), and monitors adverse event reports from companies, healthcare providers, and consumers.
If a product is found unsafe or non-compliant, the FDA can work with the company to correct the issue, request a voluntary recall, or take direct action to remove the product from the market.
Benefits and Risks: What Brands Should Know
Dietary supplements can help address nutrient gaps and are commonly used to support cardiovascular, bone, and immune health.
But not every ingredient or claim is risk-free. Some supplements interact with medications, affect lab test results, or carry risk during surgical procedures. Consumers should be cautious of products that combine multiple active ingredients, exceed labeled dosages, or make claims that sound too strong to be backed by the underlying research.
For brands, this translates directly into labeling discipline: dosage instructions, interaction warnings where relevant, and claims that stay within what the evidence and the regulatory category actually support.
When This Guidance Does Not Apply
This guide covers standard dietary supplement compliance under DSHEA. It does not cover:
- Products making disease treatment or prevention claims, which are regulated as drugs regardless of how they’re marketed
- Infant formula and medical foods, which follow separate FDA frameworks
- Products already the subject of an FDA warning letter or Import Alert, which require a different remediation path. See our FDA import detentions guide for that process.
Frequently Asked Questions
Do dietary supplements need FDA approval before selling in the U.S.?
No. Under DSHEA, the FDA does not pre-approve dietary supplements for safety, efficacy, or labeling before market entry, unlike drugs, which require agency approval first. This means a company can begin selling a supplement without FDA sign-off. It does not mean the product is exempt from regulation. The manufacturer and importer are fully responsible for facility registration, accurate Supplement Facts labeling, FSVP compliance for imported products, and any required claim notifications before the first unit ships. The FDA’s regulatory role begins after the product is already on the market, through inspections, label review, and adverse event monitoring, rather than through a pre-market review process. Brands that treat the absence of approval as the absence of obligations are the ones most likely to face a compliance issue after launch, often without realizing anything was missing.
What is FDA facility registration for dietary supplements?
FDA facility registration is a mandatory requirement for any facility that manufactures, processes, packs, or holds dietary supplements intended for the U.S. market, the same obligation that applies to other food facilities under U.S. law. Registration must be renewed every two years, and a facility located outside the U.S. must designate a U.S. agent as its point of contact with the FDA. Facility registration is separate from product-level requirements like labeling and claim notifications, and separate from FSVP, which applies to the importer rather than the manufacturing facility itself. A dietary supplement brand typically needs all three in place, not just one, before a shipment can clear U.S. customs without issue. Missing any single piece can hold up a shipment even when the product itself is fully compliant.
What is a structure/function claim notification and when is it required?
A structure/function claim notification is a mandatory filing required under 21 CFR 101.93(a) whenever a dietary supplement label carries a structure/function claim, a general well-being claim, or a classical nutrient deficiency claim. The company must submit the notification to the FDA within 30 days of first marketing the product with that claim, along with the required boldface disclaimer stating the claim hasn’t been evaluated by the FDA and the product isn’t intended to diagnose, treat, cure, or prevent disease. This requirement catches many first-time supplement brands off guard, since there’s no pre-market approval process to prompt it. Missing the 30-day window is a compliance gap the FDA can act on even if the underlying claim itself is accurate and the product is otherwise safe. It’s one of the most commonly overlooked filings in the entire supplement launch process.
Does a dietary supplement importer need FSVP compliance?
Yes. Dietary supplements imported into the United States are subject to the Foreign Supplier Verification Program, the same requirement that applies to other imported food products. The importer of record must have a supplier verification program in place, documented evidence of supplier audits, and a Letter of Consent on file before the shipment arrives, not after. FDA product registration and FSVP compliance are separate obligations, and completing one does not satisfy the other. A supplement can have a fully registered facility and a compliant label and still face detention at the U.S. border if the FSVP documentation for the importer of record is missing or incomplete. This is one of the most common gaps we see in shipments that get held at U.S. ports.
When does a supplement’s claims cross into OTC drug territory?
A dietary supplement’s claims cross into OTC drug territory when the label states or implies that the product treats, cures, prevents, or alleviates symptoms of a disease, regardless of what the product actually contains. The FDA classifies products based heavily on their claims, not solely on their ingredients, so two nearly identical formulations can end up in different regulatory categories depending on how they’re marketed. Once a product is classified as a drug, it becomes subject to drug-level requirements, which are significantly more demanding and time-consuming than supplement compliance, often adding months or years to market entry. Reviewing proposed claims against FDA guidance during R&D, before a label is finalized, is the most reliable way to keep a product in the supplement category and avoid an unplanned drug review pathway.
Should a brand use a label review service before shipping to the U.S.?
Label review isn’t a mandatory FDA filing on its own, so technically a brand can skip it, but doing so is a real risk, not a formality being skipped. GOL recommends label review for all regular clients and requires it for anyone using our FSVP service, since the FSVP importer of record carries legal responsibility for the products it brings in. We’ve seen brands skip it after doing their own internal review, only to have FDA reject the shipment over issues like an incorrectly formatted Supplement Facts panel or a declared value that didn’t match the value determined during FDA’s review, resulting in a destroyed shipment. The risk has increased for e-commerce brands specifically: since July 9, 2025, FDA-regulated shipments are no longer exempt from full review under the Section 321 de minimis threshold, regardless of declared value.
Work With GOL on Dietary Supplement Compliance
GOL Solution has supported dietary supplement brands and manufacturers exporting to the U.S. for over 24 years, with teams in Singapore, Vietnam, and the United States. We handle facility registration, label and claims review, structure/function claim filings, and FSVP compliance, and we support brands earlier in the process by reviewing ingredients and claims during R&D before formulation is locked.
If you’re preparing to launch a dietary supplement in the U.S. or want to confirm your current filings are complete, contact our team for an initial review.
